The long-standing assumption that women face worse Alzheimer's disease outcomes simply because they live longer may be fundamentally incomplete. Emerging evidence suggests female biology confers a form of clinical resilience — an ability to sustain cognitive function even as toxic amyloid and tau pathology accumulates — that reframes how researchers and clinicians should interpret sex-based disparities in dementia incidence and progression.
This JAMA Perspective examines the paradox at the heart of female Alzheimer's risk: women carry a disproportionate burden of Alzheimer's pathology and account for roughly two-thirds of all diagnosed cases, yet mounting neuroimaging and biomarker data indicate that women often maintain cognitive performance at equivalent or higher pathological loads compared to men. This disconnect between pathological burden and clinical expression — sometimes termed "cognitive reserve" or "resilience" — appears to operate through mechanisms tied to female biology, potentially including hormonal influences, differential synaptic density, and X-chromosome-linked neuroprotective gene expression. The Perspective points to this resilience as a double-edged phenomenon: women may tolerate more silent pathology before symptom onset, compressing their symptomatic disease trajectory and potentially delaying diagnosis until later, more severe stages.
This analysis sits within a rapidly evolving conversation about sex as a biological variable in neurodegeneration. It challenges the dominant longevity-confound explanation while raising important methodological questions: if women are being diagnosed later in their pathological disease course, standard cognitive screening tools calibrated on mixed-sex populations may systematically underdetect early-stage Alzheimer's in women. The implications for anti-amyloid therapies — which appear most effective at early intervention — are significant. This is a conceptually important reframing, though the Perspective format means it synthesizes existing evidence rather than presenting new trial data, warranting follow-up with prospective longitudinal cohort studies stratified by sex and hormonal status.